Keranetics
Winston-Salem, US · Founded 2008 · Delaware LLC
KeraNetics develops keratin-based medical products for wound care, with its lead product KeraStat Cream, an FDA-cleared prescription treatment for managing radiation dermatitis in cancer patients undergoing radiotherapy. The company originated from work with the Wake Forest Institute for Regenerative Medicine to treat battlefield injuries and serves patients and healthcare providers in oncology.
Founders & leadership
CW
Charles W JohnsonExecutive
KD
Kim D WestmorelandExecutive
GM
Graeme M KeithNamed on SEC filing
ME
Mark E Van DykeNamed on SEC filing
Board
DE
Donald E FlowBoard director
GM
Graeme M Keith, Jr.Board director
JD
J. Douglas CraftBoard director
LA
L Andrew KomanBoard director
WA
William A HawkinsBoard director
RH
Richard H Blank, Jr.Board director
Reported raises · per SEC filings
Form D private placements$10.3M disclosed across 3 rounds · 2011–2017
▶$2.2MraisedJul 2018 · 22 investors · BiotechnologyRule 506(b)
▶$2.2MraisedJul 2018 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Donald E FlowDirector
- Charles W JohnsonDirector
- Graeme M Keith, Jr.Director
- William A HawkinsDirector
- L Andrew KomanDirector
- J. Douglas CraftDirector
- Kim D WestmorelandExecutive Officer, Director, Promoter
- Richard H Blank, Jr.Director
- Offering amount
- $2.5M
- Amount sold
- $2.2M
- Proceeds to insiders
- $150K
- First sale
- Feb 2017
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$3.4MraisedMar 2016 · 37 investors · BiotechnologyRule 506(b)
▶$3.4MraisedMar 2016 · 37 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- J. Douglas CraftDirector
- Donald E FlowDirector
- L Andrew KomanDirector
- William A HawkinsDirector
- Charles W JohnsonExecutive Officer, Director, Promoter
- Graeme M Keith, Jr.Director
- Kim D WestmorelandExecutive Officer, Director, Promoter
- Richard H Blank, Jr.Director
- Offering amount
- $4M
- Amount sold
- $3.4M
- Proceeds to insiders
- $275K
- First sale
- Mar 2015
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$4.7MraisedJan 2012 · 26 investors · BiotechnologyRule 506(b)
▶$4.7MraisedJan 2012 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Graeme M KeithDirector
- L Andrew KomanExecutive Officer, Director
- Donald E FlowDirector
- Kim D WestmorelandExecutive Officer, Director, Promoter
- Charles W JohnsonExecutive Officer, Director, Promoter
- Mark E Van DykeExecutive Officer, Director
- William A HawkinsDirector
- Offering amount
- $7M
- Amount sold
- $4.7M
- Proceeds to insiders
- $550K
- First sale
- Dec 2011
- Incorporated
- Limited Liability Company, Delaware, 2008
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapMD Anderson Cancer Center43 shared keywordsUT MD Anderson is a cancer hospital providing cancer treatment, prevention, clinical care, and research, including new therapies and clinical trials for cancer patients. It is ranked among the top hospitals in the U.S. for cancer care.
Cancerresearchuk38 shared keywordsCancer Research UK funds research across discovery, detection, prevention and treatment of cancer to improve patient outcomes and extend survival. It operates as a research funder and scientific organization serving academic and clinical researchers.
Companies competing with Keranetics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 17 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| Department of DefenseDefense Health Program | Phase II | 2020 | $699.1K |
| Department of DefenseDefense Health Program | Phase II | 2017 | $948.8K |
| U.S. ArmyArmy | Phase II | 2016 | $998.8K |
| Department of DefenseDefense Health Program | Phase II | 2015 | $1000K |
| Department of DefenseDefense Health Program | Phase II | 2015 | $999.7K |
| Department of DefenseDefense Health Program | Phase I | 2014 | $150K |
| U.S. ArmyArmy | Phase I | 2014 | $99.9K |
| U.S. ArmyArmy | Phase II | 2013 | $751.6K |
| Department of DefenseDefense Health Program | Phase I | 2013 | $149.8K |
| Department of DefenseDefense Health Program | Phase II | 2012 | $1000K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2012 | $778K |
| U.S. ArmyArmy | Phase I | 2012 | $149.9K |
| Department of DefenseDefense Health Program | Phase I | 2012 | $149.5K |
| Department of DefenseDefense Health Program | Phase II | 2011 | $750K |
| Department of DefenseDefense Health Program | Phase I | 2011 | $149.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $232.6K |
| U.S. ArmyArmy | Phase I | 2010 | $99.3K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Keranetics do?
- KeraNetics develops keratin-based medical products for wound care, with its lead product KeraStat Cream, an FDA-cleared prescription treatment for managing radiation dermatitis in cancer patients undergoing radiotherapy. The company originated from work with the Wake Forest Institute for Regenerative Medicine to treat battlefield injuries and serves patients and healthcare providers in oncology.
- How much funding has Keranetics raised?
- Keranetics has disclosed $10.3M raised across 3 rounds.
- Where is Keranetics headquartered?
- Keranetics is headquartered in Winston-Salem, US.